MedTrace Logo

Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease

NCT00738179 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2500

Last updated 2015-02-06

No results posted yet for this study

Summary

Obstructive Sleep Apnea (OSA) is a condition in which a person stops breathing for several seconds at a time due to relaxation of the throat muscles. This can occur many times during sleep. It is known to cause sleepiness and poor concentration during the day. Research indicates that OSA may be a modifiable risk factor for cardiovascular disease due to its association with hypertension, stroke, heart attack and sudden death. The standard therapy for symptomatic OSA is continuous positive airway pressure (CPAP). CPAP has been shown to effectively reduce snoring, obstructive episodes and daytime sleepiness and to modestly reduce blood pressure and other risk factors for cardiovascular disease. The overall aim of SAVE is to determine if CPAP can reduce the risk of heart attack, stroke or heart failure for people with OSA.

Conditions

Interventions

DEVICE

Continuous Positive Airway Pressure (CPAP)

CPAP worn nightly

OTHER

Standard care

Standard care of cardiovascular risk factors

Sponsors & Collaborators

  • Philips Respironics

    collaborator INDUSTRY

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • ResMed

    collaborator INDUSTRY

  • Fisher and Paykel Healthcare

    collaborator INDUSTRY

  • The George Institute

    collaborator OTHER

  • Health Research Council, New Zealand

    collaborator OTHER

  • Adelaide Institute for Sleep Health

    lead OTHER

Principal Investigators

  • R D McEvoy · Adelaide Institute for Sleep Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Australia
  • Brazil
  • China
  • India
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00738179 on ClinicalTrials.gov